In breast cancer cell models, XAV939 increased Axin protein and inhibited Wnt3a-driven transcriptional responses. In MDA-MB-231 cells, Wnt reporter inhibition persisted across the tested serum concentrations. [2]
XAV939 inhibited MDA-MB-231 growth in low serum (72-h growth IC50, 1.5 μM). Growth inhibition was absent under optimal serum in MDA-MB-231, DLD-1 and SW480 cells, illustrating that pathway inhibition does not guarantee growth suppression. [2]
Enzyme inhibition and PARP-family selectivity
Biochemical assay · Recombinant human TNKS1 SAM–ART, TNKS2 ART, and full-length PARP1/PARP2 [1]
XAV939 inhibited both tankyrases and full-length PARP1/2. The construct-dependent comparison limits claims of tankyrase selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series; IC50 is an assay endpoint.
- Exposure duration
- 15 min preincubation before NAD+ addition.
- Method
- ADP-ribosylation assay; NAD+ at or below each construct’s KM.
- Vehicle
- 1% DMSO; same-batch DMSO controls.
- Reported limits
- Individual XAV939 concentration series and enzyme-specific reaction durations not transcribed; SI not retrieved.
Methods and source locations
Compound reported in the paper: XAV 939; Compound label in the paper: XAV939
Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.
Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)
TNKS1 SAM–ART inhibition: Table 3 reported fit; not a cellular treatment dose. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)
TNKS2 ART inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)
Full-length PARP1 inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)
Full-length PARP2 inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)
Axin stabilization and Wnt-response inhibition
Cell-based study · Human MDA-MB-231 breast cancer cells; MCF-7 and murine EMT6 provide protein-response context. [2]
XAV939 increased Axin protein and suppressed Wnt3a-driven transcriptional responses. In MDA-MB-231 cells, reporter inhibition persisted across the tested serum conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM for protein/target-gene experiments; 1 or 5 μM in the serum-comparison reporter experiment.
- Exposure duration
- Overnight; Figure 1 also tests Wnt3a for the last 4 h.
- Method
- Immunoblot; normalized TOPFLASH/Renilla reporter and RT-PCR.
- Vehicle
- DMSO control.
- Co-treatment
- Wnt3a-conditioned medium; control conditioned medium comparators.
- Reported limits
- No isolated-ligand dose or exact overnight duration specified in these captions.
Methods and source locations
Compound reported in the paper: XAV 939; Compound label in the paper: XAV939
Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.
Figures 1A–C and 2C–D; Results: XAV939 increases Axin levels / inhibition of Wnt signaling; Methods: Compounds, Transfections and Reporter assays
Axin protein response: Actin loading control; Wnt3a-present/absent comparisons. — Figure 1A–C and caption
Wnt3a-induced TOPFLASH activity in MDA-MB-231 cells: Firefly normalized to Renilla; means ± SD of three replicates. No exact inhibition percentage inferred. — Figure 2C and caption
Serum-dependent growth inhibition
Cell-based study · MDA-MB-231 breast cancer cells; DLD-1 and SW480 colorectal cancer cells under optimal serum. [2]
Growth inhibition in low-serum MDA-MB-231 cells did not persist under optimal serum. This limits generalization from Wnt-response inhibition to antiproliferative activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series plotted in Figures 5B and 6; no single treatment dose.
- Exposure duration
- 72 h
- Method
- Sulforhodamine B growth assay.
- Vehicle
- DMSO-normalized growth.
- Co-treatment
- XAV939 tested alone; 21H7 is a separate comparator, not a combination.
- Reported limits
- Full per-point concentrations not transcribed from logarithmic curves.
Methods and source locations
Compound reported in the paper: XAV 939; Compound label in the paper: XAV939
Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.
Figures 5B and 6A–C and captions; Methods: Cell proliferation and colony growth assays; Results: XAV939 inhibits the growth of MDA-MB-231 breast cancer cells
MDA-MB-231 growth in 1.25% FBS: SRB at 72 h; explicitly printed IC50. — Figure 5B inset and caption
Growth at 5% FBS (MDA-MB-231) or 10% FBS (DLD-1, SW480): SRB at 72 h; means ± SD from three independent experiments performed in triplicate. 21H7 inhibited growth in the same assays. — Figure 6A–C and caption